Published in BMC Infect Dis on December 06, 2013
Vitamin D and bone loss in HIV. Curr Opin HIV AIDS (2016) 0.78
Vitamin D and Infectious Diseases: Simple Bystander or Contributing Factor? Nutrients (2017) 0.75
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10
Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA (2010) 11.59
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet (2007) 9.61
Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med (2009) 5.63
Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med (2011) 3.84
Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) (2009) 3.51
Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med (2004) 3.45
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol (2013) 2.64
Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS (2010) 2.57
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS (2008) 2.01
Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis (2011) 2.00
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr (2007) 1.83
Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis (2011) 1.83
Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis (2005) 1.80
Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res (2000) 1.66
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol (2005) 1.37
Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr (2008) 1.26
The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab (2011) 1.22
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS (2010) 1.19
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther (2011) 1.14
The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther (2007) 1.13
Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab (2007) 1.12
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther (2012) 1.01
Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr (2011) 1.00
Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int (2004) 0.98
Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials (2013) 0.95
Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci (2013) 0.94
Effect of vitamin D supplementation on vitamin D status and bone turnover markers in young adults. Eur J Clin Nutr (2006) 0.93
Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci (2013) 0.91
Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol (2013) 0.90
Vitamin D signaling in osteocytes: effects on bone and mineral homeostasis. Bone (2012) 0.89
Efficacy and safety of oral continuous low-dose versus short-term high-dose vitamin D: a prospective randomised trial conducted in a clinical setting. Med J Aust (2010) 0.89
The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med (2008) 0.88
Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int (2012) 0.86
Bone, fracture and frailty. Curr Opin HIV AIDS (2011) 0.86
Treatment of hypovitaminosis D with pharmacologic doses of cholecalciferol, oral vs intramuscular; an open labeled RCT. Clin Endocrinol (Oxf) (2013) 0.85
Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int (2012) 0.84
The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int (1996) 0.82
Severe vitamin D-deficiency and increased bone turnover in patients with hepatitis B from northeastern China. Endocr Res (2013) 0.78
One year B and D vitamins supplementation improves metabolic bone markers. Clin Chem Lab Med (2013) 0.78
The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial. AIDS Res Hum Retroviruses (2013) 0.77
Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes (2012) 0.77
[Hypercalcemia following prophylactic vitamin D administration]. Kinderarztl Prax (1986) 0.76
Selenium and the course of mild Graves' orbitopathy. N Engl J Med (2011) 3.06
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care (2008) 2.22
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS (2010) 1.45
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (2010) 1.30
The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis (2008) 1.25
Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr (2011) 1.00
Role of biofilms in neurosurgical device-related infections. Neurosurg Rev (2005) 0.98
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS (2011) 0.89
Opportunistic infections: an update. J HIV Ther (2002) 0.87
Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. Eur J Clin Pharmacol (2012) 0.87
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Res Hum Retroviruses (2010) 0.83
Donor-to-host transmission of Candida glabrata to both recipients of corneal transplants from the same donor. Cornea (2009) 0.82
Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antivir Ther (2010) 0.80
Evaluating the optimal timing of surgical antimicrobial prophylaxis: study protocol for a randomized controlled trial. Trials (2014) 0.79
Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. Eur J Clin Pharmacol (2015) 0.78
Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS (2005) 0.78
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. Antivir Ther (2012) 0.77
Obstructive jaundice caused by enteropathy-associated T-cell lymphoma in a patient with celiac sprue. J Gastroenterol (2004) 0.76
Review of quality deficiencies found in active pharmaceutical ingredient master files submitted to the WHO Prequalification of Medicines Programme. J Pharm Pharm Sci (2014) 0.75
The biowaiver procedure: its application to antituberculosis products in the WHO prequalification programme. J Pharm Sci (2010) 0.75
Multifocal thrombophlebitis and deep vein thrombosis in primary cytomegalovirus infection--a histopathological analysis. Thromb Haemost (2008) 0.75